Evidence map›Paper›PMID 34755033›Full record

ArticleJournal of the Canadian Association of Gastroenterology2021

Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary.

M Ellen Kuenzig, Joseph W Windsor, Lisa Barrett, Charles N Bernstein, Alain Bitton, Matthew W Carroll, Usha Chauhan, Stephanie Coward, Sharyle Fowler, Jean-Eric Ghia and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Canadian Association of Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD.Journal of the Canadian Association of Gastroenterology · 2023
    Review
  3. The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary.Journal of the Canadian Association of Gastroenterology · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 16 institutions in 3 countries.

M Ellen KuenzigSickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-3984-8426
Joseph W WindsorDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID https://orcid.org/0000-0002-7539-9103
Lisa BarrettDepartment of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Charles N BernsteinDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID https://orcid.org/0000-0001-8041-3574
Alain BittonDepartment of Medicine, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Matthew W CarrollDepartment of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
Usha ChauhanHamilton Health Science, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.ORCID https://orcid.org/0000-0002-7193-0657
Stephanie CowardDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID https://orcid.org/0000-0003-0675-7226
Sharyle FowlerDepartment of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Jean-Eric GhiaDepartment of Immunology and Internal Medicine section of Gastroenterology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba and University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada.
Rose GeistDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Deanna L GibsonDepartment of Biology, Faculty of Science; Department of Medicine, Faculty of Medicine, The University of British Columbia, Okanagan campus, Kelowna, British Columbia, Canada.
Lesley A GraffUniversity of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.
Anne M GriffithsSickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
James Guoxian HuangSickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
Jennifer L JonesDepartment of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Reena KhannaLondon Health Sciences Centre-University Campus, Western University, London, Ontario, Canada.
Peter L LakatosDepartment of Medicine, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0002-3948-6488
Kate LeeCrohn's and Colitis Canada, Toronto, Ontario, Canada.
David R MackCHEO Inflammatory Bowel Disease Centre and Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
John K MarshallHamilton Health Science, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Mariam S MukhtarDepartment of Internal Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Sanjay K MurthyThe Ottawa Hospital IBD Centre, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Geoffrey C NguyenMount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0001-7083-7429
Remo PanaccioneDivision of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Cynthia H SeowDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID https://orcid.org/0000-0002-1551-9054
Harminder SinghDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID https://orcid.org/0000-0002-9354-2356
Parul TandonDivision of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-0021-2161
Laura E TargownikDivision of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Sandra ZelinskyDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.
Eric I BenchimolSickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0001-8855-3598
Gilaad G KaplanDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID https://orcid.org/0000-0003-2719-0556
University of Calgary · CAUniversity of Manitoba · CAMount Sinai Hospital · CAUniversity of Toronto · CADalhousie University · CAMcMaster University · CASickKids Foundation · CAUniversity of Ottawa · CACrohn's and Colitis Canada · CAKing Abdulaziz University · SAMcGill University Health Centre · CASemmelweis University · HUUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Saskatchewan · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persons with inflammatory bowel disease (IBD) make up more than 0.75% of the Canadian population in 2021. Early in the COVID-19 pandemic, individuals with IBD, particularly those on immunosuppressive therapies, were concerned that their health status may place them at higher risk of contracting COVID-19 or experiencing more severe disease course if infected with SARS-CoV-2. In response, Crohn's and Colitis Canada developed the COVID-19 and IBD Taskforce in March 2020 to rapidly synthesize the evolving knowledge of COVID-19 as relevant to Canadians with IBD. The Taskforce communicated expert information directly to the Canadian IBD community through online tools and a webinar series. In order to understand the full impact of COVID-19 on the IBD community, Crohn's and Colitis Canada commissioned a policy report that was informed through a systematic literature review and synthesized across working groups along the following domains: Epidemiology, Children and Expectant Mothers with IBD, Seniors with IBD, Mental Health, Risk Factors and Medications, Vaccines, and Healthcare Delivery during the Pandemic and the Future Model of IBD Care. This report from Canadian physicians, researchers, and IBD community representatives highlights the physical, mental, and health systems impact of COVID-19 on the entire spectrum of the IBD community, including children, adolescents, adults, seniors, and pregnant people with IBD. This executive summary provides an overview of the crucial information from each of the chapters of the policy report, supplemented with additional information made available through Crohn's and Colitis Canada's webinar-based knowledge translation platform.

Indexed as

CoronavirusCrohn’s diseaseSARS-CoV-2Ulcerative colitis

Identifiers

PMID34755033
PMCPMC8570424
OpenAlexW3212702794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.